X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark Pharma Fact Sheet, Glenmark Pharma Financial Results - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Glenmark Pharma Fact Sheet   (GLPH)

Here is the latest financial fact sheet of Glenmark Pharma. For more details, see the Glenmark Pharma quarterly results and Glenmark Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

GLENMARK PHARMA Price History

Price Rs 606.7
Mkt Cap Rs m 164,586
Vol '000 45.4
P/E X 23.4
P/CF X 14.9
EPS (TTM) Rs 25.9
% ch % -1.5
No. of shares m 271.28
% ch week % 2.7
% ch 1-mth % -10.7
% ch 12-mth % -0.7
52 week H/L Rs 711.6/483.6
(As on Oct 16, 2018 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

GLENMARK PHARMA Financials

No. of Mths
Year Ending
12
Mar-14
*
12
Mar-15
*
12
Mar-16
*
12
Mar-17
*
12
Mar-18
*
5-Yr Chart
Click to enlarge
GLENMARK PHARMA EQUITY SHARE DATA
High Rs6128791,262993930 
Low Rs464752672729517 
Sales per share (Unadj.) Rs221.4244.4271.1325.5322.6 
Earnings per share (Unadj.) Rs20.117.526.339.328.5 
Diluted earnings per shareRs20.117.527.440.929.6 
Cash flow per share (Unadj.) Rs28.127.134.648.739.2 
Dividends per share (Unadj.) Rs2.002.002.002.002.00 
Adj. dividends per shareRs2.002.002.082.082.08 
Dividend yield (eoy) %0.40.20.20.20.3 
Book value per share (Unadj.) Rs110.086.1128.6159.2183.0 
Adj. book value per shareRs110.086.1133.8165.6190.3 
Shares outstanding (eoy) m271.22271.29282.16282.17282.17 
Bonus/Rights/Conversions  ---ESOP- 
Price / Sales ratio x2.43.33.62.62.2 
Avg P/E ratio x26.746.636.721.925.4 
P/CF ratio (eoy) x19.130.127.917.718.5 
Price / Book Value ratio x4.99.57.55.44.0 
Dividend payout %9.911.47.65.17.0 
Avg Mkt Cap Rs m145,889221,284272,778242,991204,206 
No. of employees `000NA9.510.013.013.7 
Total wages/salary Rs m10,26212,02413,78216,40818,718 
Avg. sales/employee Rs ThNM6,961.17,630.57,083.96,636.8 
Avg. wages/employee Rs ThNM1,262.51,374.81,265.41,364.7 
Avg. net profit/employee Rs ThNM499.0741.2855.1586.1 
GLENMARK PHARMA INCOME DATA
Net Sales Rs m60,05266,29876,49691,85791,031 
Other income Rs m115219200374914 
Total revenues Rs m60,16766,51676,69692,23091,945 
Gross profit Rs m10,90810,22514,37220,36716,154 
Depreciation Rs m2,1682,6002,3432,6443,019 
Interest Rs m1,8861,9021,7892,3732,856 
Profit before tax Rs m6,9695,94310,44015,72411,193 
Minority Interest Rs m00000 
Prior Period Items Rs m00000 
Extraordinary Inc (Exp) Rs m000-8100 
Tax Rs m1,5131,1903,0093,8273,155 
Profit after tax Rs m5,4564,7527,43011,0888,039 
Gross profit margin %18.215.418.822.217.7 
Effective tax rate %21.720.028.824.328.2 
Net profit margin %9.17.29.712.18.8 
GLENMARK PHARMA BALANCE SHEET DATA
Current assets Rs m47,62753,19959,04368,74669,887 
Current liabilities Rs m29,49237,11139,99327,02732,879 
Net working cap to sales %30.224.324.945.440.7 
Current ratio x1.61.41.52.52.1 
Inventory Days Days5770758581 
Debtors Days Days1311381199693 
Net fixed assets Rs m30,35717,44521,41624,13228,892 
Share capital Rs m271271282282282 
"Free" reserves Rs m21,41523,08636,01444,64351,353 
Net worth Rs m29,83323,35736,29644,92551,635 
Long term debt Rs m24,28725,74424,87345,36341,418 
Total assets Rs m86,33687,429101,929117,639125,954 
Interest coverage x4.74.16.87.64.9 
Debt to equity ratio x0.81.10.71.00.8 
Sales to assets ratio x0.70.80.80.80.7 
Return on assets %8.57.69.011.48.6 
Return on equity %18.320.320.524.715.6 
Return on capital %16.416.020.019.115.1 
Exports to sales %11.744.843.200 
Imports to sales %1.07.17.400 
Exports (fob) Rs m7,03929,72033,04400 
Imports (cif) Rs m5794,6805,67200 
Fx inflow Rs m8,52831,29936,94556,15236,317 
Fx outflow Rs m3,64110,85661,0668,0849,720 
Net fx Rs m4,88820,443-24,12248,06826,598 
GLENMARK PHARMA CASH FLOW
From Operations Rs m 8,537 4,817 3,449 6,574 16,481 
From Investments Rs m -3,681 -5,400 -8,802 -7,124 -10,133 
From Financial Activity Rs m -980 1,992 6,986 5,432 -4,685 
Net Cashflow Rs m 1,896 -311 934 1,992 1,770 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 48.3%
Foreign collaborators 0.0%
Indian inst/Mut Fund 6.9%
FIIs 34.4%
ADR/GDR 0.0%
Free float 10.5%
Shareholders 56,727
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai - 400 026
E-MAIL complianceofficer@glenmarkpharma.com WEB www.glenmarkpharma.com
TELEPHONE (022) 4018 9999 FAX (022) 4018 9986
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Karvy Computer, 17-24, Vithalrao Nagar, Madhapur, Hyderabad-81
AUDITOR Walker, Chandiok & Co.
CHM: Glenn Saldanha (MD) COMP SEC: Sanjay Kumar Chowdhary YEAR OF INC: 1977 BSE CODE: 532296 FV (Rs): 1 DIV YIELD (%): 0.3

Read: GLENMARK PHARMA 2017-18 Annual Report Analysis

More Pharmaceuticals Company Fact Sheets:   SHASUN PHARMA  PANACEA BIOTECH  INDOCO REMEDIES  TORRENT PHARMA  ORCHID PHARMA LTD  

Compare GLENMARK PHARMA With:   SHASUN PHARMA  PANACEA BIOTECH  INDOCO REMEDIES  TORRENT PHARMA  ORCHID PHARMA LTD  

Compare GLENMARK PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 297 Points Higher; Energy and Realty Stocks Witness Buying(Closing)

Share markets in India continued their momentum during closing hours and ended the day on a positive note. Sectoral indices were trading on a positive note, with stocks in the energy sector.

Views on news

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Sep 27, 2018 | Updated on Sep 27, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

GLENMARK PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 30.1% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 30.1% YoY). Sales on the other hand came in at Rs 22 bn (down 8.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.6% (Quarterly Result Update)

May 31, 2018 | Updated on May 31, 2018

For the quarter ended March 2018, GLENMARK PHARMA has posted a net profit of Rs 2 bn (down 6.6% YoY). Sales on the other hand came in at Rs 23 bn (down 7.2% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

Don't Panic in This Falling Market... Do This Instead(The 5 Minute Wrapup)

Oct 5, 2018

Find companies with long term durable moats, which are correcting with the current broader market sell-off.

Why You Should Be Excited, Not Sad, About the 30% Small Cap Crash(Profit Hunter)

Oct 4, 2018

Smallcaps have corrected over 30% since the beginning of the year. Find out why Richa Agarwal views this as an opportunity rather than a threat.

Taxpayers to pay salaries of CEOs/CIOs of Mutual Funds(The Honest Truth)

Oct 5, 2018

Ajit Dayal on the crisis in the market and in the mutual fund industry.

Why Are Investors In Sundaram Small Cap Fund Anxious(Outside View)

Oct 3, 2018

A small cap fund that aims to capitalise on emerging businesses and catch them young. However, its failure in keeping volatility under check is making its investors anxious.

Biggest Corrections in the Stock of Infibeam Avenues(Chart Of The Day)

Oct 3, 2018

Infibeam plunged over 70% last week. This was the second biggest single-day fall. But Infibeam witnessed such sharp falls earlier.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA 8-QTR ANALYSIS

COMPARE GLENMARK PHARMA WITH

MARKET STATS